ARIUS Research Inc., (TSX: ARI) a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.
More...